Abstract
ObjectiveTo investigate the feasibility of fixed dose, weight adjusted subcutaneous low molecular weight heparin (LMWH), with monitoring of anti-Xa levels and assessment of coronary patency rates after three to five...
Highlights
The mean (SEM) anti-factor Xa activity (aXa) level over 72 hours was 0.52 (0.08) U/ml; from 12 hours onwards 88% of all aXa measurements were within the target range
infarct related coronary artery (IRA) and TIMI flow results are shown in table 2
This study shows that the use of fixed dose, weight adjusted subcutaneous low molecular weight heparin (LMWH) as an adjunct to recombinant tissuetype plasminogen activator (rt-PA) thrombolytic treatment for acute myocardial infarction induces stable and predictable aXa levels within the predefined target range
Summary
Abstract Objective—To investigate the feasibility of fixed dose, weight adjusted subcutaneous low molecular weight heparin (LMWH), with monitoring of anti-Xa levels and assessment of coronary patency rates after three to five days, thereby giving an initial indication of its safety and eYcacy. Coronary angiography was performed in all patients within five days after the start of thrombolytic treatment to determine patency (TIMI 2 and 3 flow) of the infarct related artery.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
